• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

BMJ Open . 2020 Nov 12;10(11):e041989. doi: 10.1136/bmjopen-2020-041989. Fibrosis-4 index as a predictor for mortality in hospitalised patients with

tetano

Editor, Senior Moderator
BMJ Open


. 2020 Nov 12;10(11):e041989.
doi: 10.1136/bmjopen-2020-041989.
Fibrosis-4 index as a predictor for mortality in hospitalised patients with COVID-19: a retrospective multicentre cohort study


Jung Gil Park[SUP] 1 [/SUP], Min Kyu Kang[SUP] 1 [/SUP], Yu Rim Lee[SUP] 2 [/SUP], Jeong Eun Song[SUP] 3 [/SUP], Na Young Kim[SUP] 4 [/SUP], Young Oh Kweon[SUP] 2 [/SUP], Won Young Tak[SUP] 2 [/SUP], Se Young Jang[SUP] 2 [/SUP], Changhyeong Lee[SUP] 3 [/SUP], Byung Seok Kim[SUP] 3 [/SUP], Jae Seok Hwang[SUP] 4 [/SUP], Byoung Kuk Jang[SUP] 4 [/SUP], Jinmok Bae[SUP] 4 [/SUP], Ji Yeon Lee[SUP] 4 [/SUP], Jeong Ill Suh[SUP] 5 [/SUP], Soo Young Park[SUP] 6 [/SUP], Woo Jin Chung[SUP] 7 [/SUP], Daegu-Gyeongbuk Liver Study Group (DGLSG)



Affiliations

Abstract

Objective: The reliable risk factors for mortality of COVID-19 has not evaluated in well-characterised cohort. This study aimed to identify risk factors for in-hospital mortality within 56 days in patients with severe infection of COVID-19.
Design: Retrospective multicentre cohort study.
Setting: Five tertiary hospitals of Daegu, South Korea.
Participants: 1005 participants over 19 years old confirmed COVID-19 using real-time PCR from nasopharyngeal and oropharyngeal swabs.
Methods: The clinical and laboratory features of patients with COVID-19 receiving respiratory support were analysed to ascertain the risk factors for mortality using the Cox proportional hazards regression model. The relationship between overall survival and risk factors was analysed using the Kaplan-Meier method.
Outcome: In-hospital mortality for any reason within 56 days.
Results: Of the 1005 patients, 289 (28.8%) received respiratory support, and of these, 70 patients (24.2%) died. In multivariate analysis, high fibrosis-4 index (FIB-4; HR 2.784), low lymphocyte count (HR 0.480), diabetes (HR 1.917) and systemic inflammatory response syndrome (HR 1.714) were found to be independent risk factors for mortality in patients with COVID-19 receiving respiratory support (all p<0.05). Regardless of respiratory support, survival in the high FIB-4 group was significantly lower than in the low FIB-4 group (28.8 days vs 44.0 days, respectively, p<0.001). A number of risk factors were also significantly related to survival in patients with COVID-19 regardless of respiratory support (0-4 risk factors, 50.2 days; 49.7 days; 44.4 days; 32.0 days; 25.0 days, respectively, p<0.001).
Conclusion: FIB-4 index is a useful predictive marker for mortality in patients with COVID-19 regardless of its severity.

Keywords: COVID-19; Coronavirus; fibrosis; mortality; risk factors; survival.
 
Back
Top Bottom